Zostavax®

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC, University of South Florida

Conditions

Common Variable Immune DeficiencyHerpes ZosterSpecific Antibody DeficiencyX-linked Agammaglobulinemia

Phase 4

Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

CompletedNCT00681031

Merck Sharp & Dohme LLCHerpes Zoster

Start: 2008-05-14End: 2008-06-25Updated: 2021-06-29

Unknown Phase

Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older

TerminatedNCT02960399

University of South FloridaCommon Variable Immune Deficiency, Specific Antibody Deficiency, X-linked Agammaglobulinemia

Start: 2015-12-31End: 2017-12-31Updated: 2018-05-31